However, clinical data revealed that although the use of TAM in the early treatment period has apparent benefits for ER + breast cancer patients, some patients were prone to develop resistance to TAM and lead to tumor progression and metastasis [3, 4]. The gene discussed is ESR1; the disease is breast carcinoma.